MedTrace Logo

Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

NCT02940912 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-04-25

No results posted yet for this study

Summary

The purpose of the study is to demonstrate that continuous apomorphine treatment during the night compared with placebo improves sleep quality in insomniac patient with Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

Apomorphine

cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.

DRUG

Placebo

cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.

Sponsors & Collaborators

  • Clinique Beau Soleil

    lead OTHER

Principal Investigators

  • Valérie COCHEN DE COCK, PI, MD, PhD · Clinique BEAU SOLEIL, 34070 Montpellier

  • Emmanuel FLAMAND-ROZE, PI, MD, PhD · Hopital PITIE-SALPETRIERE, 75013 Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2021-01-31
Completion
2021-04-12

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02940912 on ClinicalTrials.gov